Edesa Biotech Names JSS CRO and Reaffirms Mid-2026 Phase 2 Vitiligo Trial
Edesa Biotech selected JSS Medical Research as the CRO for its Phase 2 EB06 study in moderate-to-severe nonsegmental vitiligo and began outreach to clinical sites. The company reaffirmed that site activations and patient recruitment will start mid-2026, with initial enrollment in Canada after trial application approval.
1. CRO Selection and Site Outreach
Edesa has appointed JSS Medical Research as the clinical research organization for its Phase 2 EB06 trial in moderate-to-severe nonsegmental vitiligo and has initiated outreach to potential sites and investigators.
2. Enrollment Timeline Reaffirmed
The company reaffirmed guidance that site activations and patient enrollment will commence in mid-2026, with initial trial sites launching in Canada pending clinical trial application updates.
3. Phase 2 Study Design
The randomized, placebo-controlled study will evaluate the safety and efficacy of intravenous EB06 infusions in adults with generalized vitiligo, followed by a dedicated follow-up period to assess treatment durability.
4. Pipeline Context
EB06, a monoclonal antibody targeting CXCL10, has shown depigmentation reversal in preclinical models and follows Edesa’s broader pipeline which includes daniluromer for allergic contact dermatitis and paridiprubart for acute respiratory distress syndrome.